- Home
- PCSA vs WATT Comparison
PCSA vs WATT Comparison
Compare PCSA & WATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- WATT
- Stock Information
- Founded
- PCSA 2011
- WATT 2012
- Country
- PCSA United States
- WATT United States
- Employees
- PCSA N/A
- WATT N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- WATT Radio And Television Broadcasting And Communications Equipment
- Sector
- PCSA Health Care
- WATT Technology
- Exchange
- PCSA Nasdaq
- WATT Nasdaq
- Market Cap
- PCSA 4.3M
- WATT 3.9M
- IPO Year
- PCSA N/A
- WATT 2014
- Fundamental
- Price
- PCSA $0.86
- WATT $0.47
- Analyst Decision
- PCSA Buy
- WATT Strong Buy
- Analyst Count
- PCSA 3
- WATT 2
- Target Price
- PCSA $5.00
- WATT $2.25
- AVG Volume (30 Days)
- PCSA 26.8K
- WATT 201.1K
- Earning Date
- PCSA 10-30-2024
- WATT 11-12-2024
- Dividend Yield
- PCSA N/A
- WATT N/A
- EPS Growth
- PCSA N/A
- WATT N/A
- EPS
- PCSA N/A
- WATT N/A
- Revenue
- PCSA N/A
- WATT $431,184.00
- Revenue This Year
- PCSA N/A
- WATT $95.75
- Revenue Next Year
- PCSA N/A
- WATT $834.07
- P/E Ratio
- PCSA N/A
- WATT N/A
- Revenue Growth
- PCSA N/A
- WATT N/A
- 52 Week Low
- PCSA $0.85
- WATT $0.45
- 52 Week High
- PCSA $17.40
- WATT $2.75
- Technical
- Relative Strength Index (RSI)
- PCSA 21.42
- WATT 32.37
- Support Level
- PCSA $0.85
- WATT $0.45
- Resistance Level
- PCSA $1.06
- WATT $0.58
- Average True Range (ATR)
- PCSA 0.08
- WATT 0.04
- MACD
- PCSA -0.02
- WATT -0.01
- Stochastic Oscillator
- PCSA 2.89
- WATT 12.96
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.